{"id":785161,"date":"2022-05-10T08:00:08","date_gmt":"2022-05-10T06:00:08","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/"},"modified":"2023-07-11T12:25:32","modified_gmt":"2023-07-11T10:25:32","slug":"bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/","title":{"rendered":"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress"},"content":{"rendered":"- BLAs for beti-cel for \u03b2-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 -\n\n\n- Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 -\n\n\n- Ended quarter with $312M in restricted cash, cash and cash equivalents and marketable securities -\n\nCAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or the \u201cCompany\u201d) today reported financial results and business highlights for the first quarter ended March 31, 2022, and shared recent operational progress.\n\n\n\n\u201cFor more than a decade, bluebird bio has helped chart the path for the field of gene therapy and today, we are closer
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

– BLAs for beti-cel for \u03b2-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 – – Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 – – Ended quarter with $312M in restricted cash, cash and cash […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-785161","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nbluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez\" \/>\n<meta property=\"og:description\" content=\"- BLAs for beti-cel for \u03b2-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 - - Ended quarter with $312M in restricted cash, cash and cash […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-10T06:00:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-11T10:25:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"olomaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"olomaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/\"},\"author\":{\"name\":\"olomaster\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\"},\"headline\":\"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress\",\"datePublished\":\"2022-05-10T06:00:08+00:00\",\"dateModified\":\"2023-07-11T10:25:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/\"},\"wordCount\":2169,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/\",\"name\":\"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-05-10T06:00:08+00:00\",\"dateModified\":\"2023-07-11T10:25:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\",\"name\":\"olomaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"caption\":\"olomaster\"},\"url\":\"https:\/\/bebeez.it\/en\/author\/olomaster\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/","og_locale":"en_US","og_type":"article","og_title":"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","og_description":"- BLAs for beti-cel for \u03b2-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 - - Ended quarter with $312M in restricted cash, cash and cash […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/","og_site_name":"BeBeez","article_published_time":"2022-05-10T06:00:08+00:00","article_modified_time":"2023-07-11T10:25:32+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"author":"olomaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"olomaster","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/"},"author":{"name":"olomaster","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518"},"headline":"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress","datePublished":"2022-05-10T06:00:08+00:00","dateModified":"2023-07-11T10:25:32+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/"},"wordCount":2169,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/","name":"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-05-10T06:00:08+00:00","dateModified":"2023-07-11T10:25:32+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-first-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518","name":"olomaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","caption":"olomaster"},"url":"https:\/\/bebeez.it\/en\/author\/olomaster\/"}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/785161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=785161"}],"version-history":[{"count":1,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/785161\/revisions"}],"predecessor-version":[{"id":890374,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/785161\/revisions\/890374"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=785161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=785161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=785161"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=785161"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=785161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}